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To the Editor:
We read with interest the comment by Ridker Third, the increased use of revascularization procedures, especially percutaneous coronary interventions (PCI) in the US since the time of the studies used to develop the ASCVD risk equation might also lead to further underestimation of CVD event rates in the contemporary cohorts used for validation 8 . The ASCVD risk equation was developed to predict so-called "hard" ASCVD events (i.e., myocardial infarctions, stroke or death from coronary disease or stroke). Revascularization procedures were not included as outcomes 2 . For patients with acute coronary syndromes, revascularization procedures have been shown to reduce the incidence of myocardial infarction 9 . When compared to optimal medical therapy, revascularization procedures in the setting of stable coronary disease may not delay the occurrence of a myocardial infarction 10, 11 . However, given the low rate of optimal medical therapy use in the general population 12 , revascularization procedures may be preventing the onset of some overt events in the contemporary observational cohort studies. Based on these data, it is our opinion that the increased use Further, clinical practice guidelines during the time of the validation cohorts recommended that known coronary disease be treated as a high risk condition 13 , increasing the likelihood that revascularized patients who did not have a hard outcome were initiated on statins, further contributing to lower than expected event rates preferentially among those at highest risk.
Fourth, validation of the ASCVD risk equation in the MESA and REGARDS studies relied on a short follow-up period during which there were a limited number of events. The number of events is especially modest considering that event rate estimates were generated for 16 groups defined by race, sex, and ASCVD risk categories. The most recent data lock for the REGARDS study includes additional follow-up for ASCVD events. Re-analysis of the REGARDS data using the additional events needs to be completed to provide more stable estimates that also reflect longer-term outcome event rates.
In our opinion, these four considerations lead us to the conclusion that it is premature to draw firm conclusions about potential over-estimation of risk using the new ASCVD risk equation. We look forward to using the contemporary data available from the REGARDS study to inform the ongoing discussion surrounding the new ASCVD risk 
